PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
1-Year Return
2.57%
This Quarter Return
+23.45%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$863M
AUM Growth
-$23.7M
(-2.7%)
Cap. Flow
-$142M
Cap. Flow
% of AUM
-16.47%
Top 10 Holdings %
Top 10 Hldgs %
80.4%
Holding
40
New
2
Increased
10
Reduced
8
Closed
1
Top Buys
| 1 |
ELEV
Elevation Oncology
ELEV
|
+$1.22M |
| 2 |
Generation Bio
GBIO
|
+$424K |
| 3 |
STAAR Surgical
STAA
|
+$96.6K |
| 4 |
AnaptysBio
ANAB
|
+$93.6K |
| 5 |
BLUE
bluebird bio
BLUE
|
+$72K |
Top Sells
| 1 |
Insmed
INSM
|
+$153M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$27.3M |
| 3 |
Amicus Therapeutics
FOLD
|
+$3.12M |
| 4 |
Align Technology
ALGN
|
+$2.74M |
| 5 |
eHealth
EHTH
|
+$1.66M |
Sector Composition
| 1 | Healthcare | 93.61% |
| 2 | Financials | 1.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VERV
26
DELISTED
Verve Therapeutics
VERV
| $2.81M | 0.33% |
575,817
| – | – |
|
27
Nuvation Bio
NUVB
$1.07B
| $2.26M | 0.26% |
772,652
| – | – |
|
28
Mirum Pharmaceuticals
MIRM
$3.73B
| $2.21M | 0.26% |
64,700
| – | – |
|
29
Relmada Therapeutics
RLMD
$52.8M
| $2.2M | 0.25% |
732,400
| – | – |
|
30
Taysha Gene Therapies
TSHA
$837M
| $1.82M | 0.21% |
811,268
| – | – |
|
31
Stoke Therapeutics
STOK
$1.29B
| $1.7M | 0.2% |
125,861
| – | – |
|
32
Humana
HUM
$33.2B
| $1.49M | 0.17% |
3,985
| – | – |
|
33
Travere Therapeutics
TVTX
$2.09B
| $910K | 0.11% |
110,719
| – | – |
|
34
VYNE Therapeutics
VYNE
$7.91M
| $878K | 0.1% |
445,434
| – | – |
|
35
Aldeyra Therapeutics
ALDX
$324M
| $746K | 0.09% |
225,465
| – | – |
|
36
Aclaris Therapeutics
ACRS
$211M
| $627K | 0.07% |
569,832
| – | – |
|
|
37
Generation Bio
GBIO
$39.9M
| $424K | 0.05% |
+15,048
| New | +$424K |
|
38
UroGen Pharma
URGN
$869M
| $411K | 0.05% |
24,500
| – | – |
|
|
39
Alnylam Pharmaceuticals
ALNY
$61.1B
| – | – |
-182,766
| Closed | -$27.3M |
|